Eradivir Phase 2 study of EV25 (IMAGE)

Purdue University

Eradivir Phase 2 study of EV25

Caption

Two Eradivir employees conduct research on the company’s EV25 influenza therapeutic. Eradivir, a clinical stage biotech company, will begin a Phase 2 challenge study with its antiviral therapeutic, EV25.

Credit

(Eradivir photo/Gregory Eakins)

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.